<DOC>
	<DOC>NCT00637442</DOC>
	<brief_summary>Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease</brief_summary>
	<brief_title>Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Possible Alzheimer's Disease according to ICD10 and NINCDSADRDA Underwritten study consent No treatment with acetylcholinesterase inhibitors MiniMentalState Examination: 1225 points Age: 5080 Years Orale contraception for women of childbearing age Mental Disorders Other Diseases of the CNS Severe Illness Contraindication for MRIScan Contraindication for Galantamin (Reminyl retard®) Participation at other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>